Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.630
-0.080 (-4.68%)
At close: Feb 20, 2026, 4:00 PM EST
1.660
+0.030 (1.84%)
After-hours: Feb 20, 2026, 7:13 PM EST
Coherus Oncology Revenue
Coherus Oncology had revenue of $11.57M in the quarter ending September 30, 2025, with 91.19% growth. This brings the company's revenue in the last twelve months to $83.57M, down -24.15% year-over-year. In the year 2024, Coherus Oncology had annual revenue of $266.96M with 3.78% growth.
Revenue (ttm)
$83.57M
Revenue Growth
-24.15%
P/S Ratio
0.88
Revenue / Employee
$1,757,772
Employees
158
Market Cap
243.64M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 266.96M | 9.72M | 3.78% |
| Dec 31, 2023 | 257.24M | 46.20M | 21.89% |
| Dec 31, 2022 | 211.04M | -115.51M | -35.37% |
| Dec 31, 2021 | 326.55M | -149.27M | -31.37% |
| Dec 31, 2020 | 475.82M | 119.75M | 33.63% |
| Dec 31, 2019 | 356.07M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | 1.56M | -188.55M | -99.18% |
| Dec 31, 2016 | 190.11M | 160.07M | 532.82% |
| Dec 31, 2015 | 30.04M | -1.07M | -3.42% |
| Dec 31, 2014 | 31.11M | 28.36M | 1,030.72% |
| Dec 31, 2013 | 2.75M | 852.00K | 44.87% |
| Dec 31, 2012 | 1.90M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Protalix BioTherapeutics | 61.84M |
| Silence Therapeutics | 25.83M |
| OmniAb | 21.09M |
| Sol-Gel Technologies | 18.97M |
| Opus Genetics | 14.63M |
| AC Immune | 5.48M |
| Shattuck Labs | 1.00M |
| Inhibikase Therapeutics | 1.00 |
CHRS News
- 3 days ago - Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock - GlobeNewsWire
- 8 days ago - Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 5 weeks ago - Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114) - GlobeNewsWire
- 2 months ago - Coherus Oncology: A Two-Pronged March With Mid-2026 Implications - Seeking Alpha
- 2 months ago - Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma - GlobeNewsWire
- 3 months ago - Coherus Oncology, Inc. (CHRS) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha